Square Pharma posts double-digit growth, earns Tk5,785cr in 9 months
Square Pharmaceuticals managed to post double-digit growth in revenue in the first nine months of the ongoing fiscal year.
The country's leading drugmaker published unaudited statements for the first three quarters on its website today, saying its revenue stood at Tk5,784.64 crore in July-March, marking 11% year-on-year growth.
Market insiders said during a challenging economic period marked by high inflation, the spread of diseases proved to be an advantage for drugmakers, as people were compelled to purchase medicines.
Keep updated, follow The Business Standard's Google news channel
However, Square Pharma could not shield itself from the impact of inflation, which led it to face a significant increase in expenditures for the purchase of raw materials, according to the company's financial statement.
In July-March of FY25, its profit grew by 16% year-on-year to reach Tk1,874.80 crore. At the end of March, its earnings per share stood at Tk21.15, compared to Tk18.24 a year ago.
In the January-March quarter, it earned Tk2,012.87 crore and net profit of Tk605 crore, which was 22% and 23% respectively higher from the previous year at the same time.
Earlier, it had paid a record 110% cash dividend to its shareholders for the fiscal 2023-24.
Today, its shares closed 0.19% lower at Tk215 each at the Dhaka Stock Exchange.
